SINO BIOPHARM(HK:01177) 投资界·2026-01-16 03:39Core Viewpoint - The article discusses the strategic acquisition of Hegia Biotech by China National Pharmaceutical Group, marking a significant move in the domestic pharmaceutical industry, particularly in the small nucleic acid drug sector, with a total price of 1.2 billion RMB [2][4]. Group 1: Acquisition Details - On January 13, 2025, China National Pharmaceutical Group announced the full acquisition of Hegia Biotech for 1.2 billion RMB, reinforcing its position in the small nucleic acid drug market [2][4]. - The acquisition process was notably swift, moving from initial discussions to final agreement in a short timeframe, indicating a strong strategic alignment between the two companies [3][4]. - Hegia Biotech has developed a unique delivery platform for siRNA, which is the first clinically validated system capable of long-term administration, showcasing its innovative capabilities [5]. Group 2: Leadership and Strategy - The article highlights the leadership of Xie Qirun, a member of the fourth generation of the Xie family, who has been pivotal in steering the company towards innovation and strategic acquisitions [7][9]. - Under Xie Qirun's leadership, the company has shifted its focus from generic to innovative drugs, with the number of innovative products increasing from 2 to 21 over ten years [10]. - The strategic acquisitions of Hegia and Lixin Pharmaceutical are part of a broader vision to position China National Pharmaceutical Group in the global pharmaceutical landscape, particularly targeting major markets in oncology and chronic diseases [10][11]. Group 3: Industry Context - The article draws parallels between the current acquisition strategies of Chinese pharmaceutical companies and historical moves by global pharmaceutical giants, emphasizing the growing trend of mergers and acquisitions as a core growth engine in the industry [12][13]. - It notes that the Chinese pharmaceutical sector is entering a "new era" of globalization, with a focus on innovative therapies and international market expansion [14]. - The anticipated expiration of patents for significant drugs in the coming years is expected to intensify competition for innovative sources, positioning Chinese companies favorably to participate in this global race [14].